-+ 0.00%
-+ 0.00%
-+ 0.00%

*Gilead: HCXT-2001 Has Potential as a Monotherapy or in Combination With Other Gilead Programs to Address Unmet Needs in Immune-Mediated Inflammatory Diseases >GILD

Dow Jones·10/22/2026 20:13:00

Please log in to view news